Aperio Group LLC Has $1.01 Million Holdings in Catalent, Inc. (CTLT)
Aperio Group LLC raised its stake in shares of Catalent, Inc. (NYSE:CTLT) by 9.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 25,362 shares of the company’s stock after acquiring an additional 2,274 shares during the quarter. Aperio Group LLC’s holdings in Catalent were worth $1,012,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. State of Wisconsin Investment Board bought a new position in shares of Catalent during the second quarter valued at $3,334,000. Chicago Equity Partners LLC lifted its holdings in shares of Catalent by 20.4% during the second quarter. Chicago Equity Partners LLC now owns 109,825 shares of the company’s stock valued at $3,855,000 after acquiring an additional 18,600 shares during the period. Airain ltd bought a new position in shares of Catalent during the second quarter valued at $3,524,000. Renaissance Technologies LLC bought a new position in shares of Catalent during the second quarter valued at $23,092,000. Finally, Sei Investments Co. lifted its holdings in shares of Catalent by 79,537.0% during the second quarter. Sei Investments Co. now owns 43,004 shares of the company’s stock valued at $1,509,000 after acquiring an additional 42,950 shares during the period. 95.65% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/aperio-group-llc-has-1-01-million-holdings-in-catalent-inc-ctlt/1713498.html.
A number of research analysts recently issued reports on CTLT shares. Zacks Investment Research cut Catalent from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Bank of America Corporation reaffirmed a “buy” rating and issued a $40.00 price target (up from $38.00) on shares of Catalent in a report on Tuesday, August 29th. William Blair reaffirmed an “ourperform” rating on shares of Catalent in a report on Tuesday, August 29th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $45.00 price target on shares of Catalent in a report on Tuesday, August 29th. Finally, ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a report on Thursday, September 7th. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $42.11.
In other Catalent news, SVP Christine Dolan sold 1,594 shares of the business’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total transaction of $61,767.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.70% of the company’s stock.
Shares of Catalent, Inc. (CTLT) opened at $38.20 on Friday. The firm has a market capitalization of $5,075.21, a PE ratio of 26.71, a price-to-earnings-growth ratio of 2.45 and a beta of 1.49. Catalent, Inc. has a twelve month low of $22.94 and a twelve month high of $43.39. The company has a current ratio of 2.91, a quick ratio of 2.49 and a debt-to-equity ratio of 2.01.
Catalent (NYSE:CTLT) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The firm had revenue of $543.90 million during the quarter, compared to analysts’ expectations of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.16 EPS. equities analysts anticipate that Catalent, Inc. will post 1.46 earnings per share for the current fiscal year.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLT).
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.